EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte Studie

Metformin with neoadjuvant chemotherapy in localized triple‐negative and Her2neu‐positive breast cancer: A prospective phase 2 open‐label randomized controlled trial (McBETH)

B M Mouna, Atul Batra, Vinod Sharma iD, Babita Kataria, Ajay Gogia, Jyoti Sharma, Aparna Sharma, Ashutosh Mishra, Jyoutishman Saikia, Suryanarayana Deo, Supriya Mallick, Dayanand Sharma und 5 weitere

Cancer · 2025

DOI: 10.1002/cncr.70205 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer, 2025. Verfasst von B M Mouna und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, BRAIRCH, All India Institute of Medical Sciences, New Delhi, India. Hauptthemen laut MEDLINE: Metformin, Neoadjuvant Therapy, Erb-b2 Receptor Tyrosine Kinases, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

HER2‐positive and triple‐negative breast cancers (TNBC) are aggressive subtypes with poor outcomes. Metformin, a commonly used antidiabetic agent, has demonstrated anticancer potential in preclinical studies. This trial evaluated whether the addition of metformin to neoadjuvant chemotherapy (NACT) improves pathological complete response (pCR) rates in nondiabetic patients with localized HER2‐positive or TNBC. Patients and Methods In this open‐label, phase 2 randomized controlled trial, 242 chemotherapy‐naïve, nondiabetic women aged 18–65 years with localized, resectable HER2‐positive or TNBC were randomized 1:1 to receive standard NACT with or without metformin (850 mg orally twice daily until surgery). The primary endpoint was pCR (ypT0/ypN0). Secondary endpoints included subgroup pCR rates, clinical response, breast‐conserving surgery rates, adverse events, patient‐reported outcomes (ESAS‐r), and cognitive function (FACT‐Cog v3).

Results

A total of 112 patients in the metformin arm and 115 in the standard arm underwent surgery and were included in the efficacy analysis. The metformin group had a higher proportion of advanced T3/T4 tumors (55.4% vs. 42.3%). Overall pCR rates were 43.7% in the metformin group and 41.7% in the control group ( p = .75). In the HER2‐positive subgroup, pCR was higher with metformin (46.3% vs. 36.5%, p = .27). Breast‐conserving surgery rates, clinical response, and patient‐reported outcomes were similar between groups. Metformin was well tolerated; fewer patients experienced peripheral neuropathy (37.2% vs. 45.5%), but diarrhea was more frequent (26.6% vs. 10.7%).

Conclusion

Metformin did not significantly improve pCR when added to standard NACT. However, trends in HER2‐positive patients and reduced neuropathy merit further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminNeoadjuvant TherapyErb-b2 Receptor Tyrosine KinasesTriple Negative Breast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMiddle AgedAdultAgedProspective StudiesYoung AdultAdolescentTreatment OutcomeChemotherapy, Adjuvant

Stichwörter der Autor:innen

Her2 neubreastmetforminneo‐adjuvanttriple negative

Substanzen

MetforminErb-b2 Receptor Tyrosine KinasesERBB2 protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, BRAIRCH, All India Institute of Medical Sciences, New Delhi, India.
  • Department of Medical Oncology, National Cancer Institute, AIIMS - Jhajjar Campus, All India Institute of medical Sciences, Jhajjar, Haryana, India.
  • Department of Surgical Oncology, National Cancer Institute, AIIMS - Jhajjar Campus, All India Institute of medical Sciences, Jhajjar, Haryana, India.
  • Department of Surgical Oncology, BRAIRCH, All India Institute of Medical Sciences, New Delhi, India.
  • Department of Radiation Oncology, National Cancer Institute, AIIMS - Jhajjar Campus, All India Institute of medical Sciences, Jhajjar, Haryana, India.
  • Department of Radiation Oncology, BRAIRCH, All India Institute of Medical Sciences, New Delhi, India.

ORCID-Profile: Vinod Sharma, Akash Kumar

Zitieren

APA

Mouna, B. M., Batra, A., Sharma, V., Kataria, B., Gogia, A., Sharma, J., Sharma, A., Mishra, A., Saikia, J., Deo, S., Mallick, S., Sharma, D., Khadgawat, R., Upadhyay, A. D., Kaur, S., Mathur, S., & Kumar, A. (2025). Metformin with neoadjuvant chemotherapy in localized triple‐negative and Her2neu‐positive breast cancer: A prospective phase 2 open‐label randomized controlled trial (McBETH). Cancer. https://doi.org/10.1002/cncr.70205

Vancouver

Mouna BM, Batra A, Sharma V, Kataria B, Gogia A, Sharma J, et al. Metformin with neoadjuvant chemotherapy in localized triple‐negative and Her2neu‐positive breast cancer: A prospective phase 2 open‐label randomized controlled trial (McBETH). Cancer. 2025. doi:10.1002/cncr.70205

BibTeX
@article{Mouna2025,
  author = {Mouna, B M and Batra, Atul and Sharma, Vinod and Kataria, Babita and Gogia, Ajay and Sharma, Jyoti and Sharma, Aparna and Mishra, Ashutosh and Saikia, Jyoutishman and Deo, Suryanarayana and Mallick, Supriya and Sharma, Dayanand and Khadgawat, Rajesh and Upadhyay, Ashish Dutt and Kaur, Simran and Mathur, Sandeep and Kumar, Akash},
  title = {Metformin with neoadjuvant chemotherapy in localized triple‐negative and Her2neu‐positive breast cancer: A prospective phase 2 open‐label randomized controlled trial (McBETH)},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.70205}
}
Kostenlos starten →